Showing 1,601 - 1,620 results of 11,397 for search 'significantly ((((((lower decrease) OR (we decrease))) OR (mean decrease))) OR (linear decrease))', query time: 0.57s Refine Results
  1. 1601

    Top-level overview for ADHD classification study. by Ahmed Akib Jawad Karim (20427740)

    Published 2025
    “…Referring to LastBERT, a customized student BERT model, we significantly lowered model parameters from 110 million BERT base to 29 million-resulting in a model approximately 73.64% smaller. …”
  2. 1602
  3. 1603
  4. 1604

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
  5. 1605

    Original data2. by Lan Zeng (638254)

    Published 2025
    “…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”
  6. 1606

    Original data1. by Lan Zeng (638254)

    Published 2025
    “…<div><p>Diabetic retinopathy (DR) is a leading cause of blindness. We hypothesised that the long non-coding RNA <i>RP11-502I4.3</i> may be involved in angiogenesis associated with DR. …”
  7. 1607
  8. 1608

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  9. 1609

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  10. 1610

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  11. 1611

    Questionnaire description. by Cristobal Padilla-Fortunatti (21376807)

    Published 2025
    “…<div><p>Background</p><p>During the last decades, intensive care unit (ICU) mortality rates have significantly decreased but this progress has come with unintended consequences for patients and their caregivers. …”
  12. 1612
  13. 1613
  14. 1614
  15. 1615

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  16. 1616
  17. 1617
  18. 1618
  19. 1619
  20. 1620